Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Completed · Phase 3 · Has a placebo group

Conditions studied: Major Depressive Disorder

In brief

The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.

Key facts

Study ID

NCT00863798

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

682

Starts

2009-04-01

Expected to finish

2010-03-01

Last updated by the study team

2011-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening).
• Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of >= 20.
• Clinical Global Impressions Scale-Severity (CGI-S) score of >= 4.

You may not qualify if…

• Clinical instability (25% or greater increase/decrease in HAM-D 17 total score from screening to baseline).
• Significant risk of suicide as assessed by clinician judgment, HAM-D 17 and Columbia Suicide-Severity Rating Scale scores Other eligibility criteria also apply.

Where it is running

• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Encino, California, United States
• Pfizer Investigational Site — Newport Beach, California, United States
• Pfizer Investigational Site — Redlands, California, United States
• Pfizer Investigational Site — Upland, California, United States
• Pfizer Investigational Site — Aurora, Colorado, United States
• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — Cromwell, Connecticut, United States
• Pfizer Investigational Site — Maitland, Florida, United States
• Pfizer Investigational Site — North Miami, Florida, United States
• Pfizer Investigational Site — South Miami, Florida, United States
• Pfizer Investigational Site — Indianapolis, Indiana, United States
• Pfizer Investigational Site — St Louis, Missouri, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — Staten Island, New York, United States
• Pfizer Investigational Site — Toledo, Ohio, United States
• Pfizer Investigational Site — Eugene, Oregon, United States
• Pfizer Investigational Site — Portland, Oregon, United States
• Pfizer Investigational Site — Salem, Oregon, United States
• Pfizer Investigational Site — Media, Pennsylvania, United States
• Pfizer Investigational Site — Herndon, Virginia, United States
• Pfizer Investigational Site — Midlothian, Virginia, United States
• Pfizer Investigational Site — Middleton, Wisconsin, United States
• Pfizer Investigational Site — Waukesha, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.